|
Penny Heaton is responsible for all medical and regulatory affairs at Novavax and leads the clinical development programs for the company's pandemic and seasonal influenza vaccines. She joined Novavax after a seven-year career at Merck & Co.’s Research Laboratories where she served as senior director of vaccines clinical research. While at Merck she oversaw all aspects of the global development and regulatory approvals of RotaTeq the company’s vaccine for Rotavirus which has been filed in more than 100 countries.
A graduate of the University of the Louisville School of Medicine in Kentucky Dr. Heaton began her career at the U.S. Centers for Disease Control and Prevention as a medical officer in the Foodborne and Diarrheal Diseases Branch of the Epidemic Intelligence Service. She was responsible for investigating disease outbreaks as well as conducting surveillance and epidemiologic studies. She is a member of the Pediatric Infectious Diseases Society and a fellow of the American Academy of Pediatrics.
| 